Cancer is rarely the result of a single mutation in a single gene. Rather, tumors arise from the complex interplay between any number of mutually exclusive abnormal changes in the genome, the combinations of which can be unique to each individual patient. To better characterize the functional context of genomic variations in cancer, researchers at University of California San Diego School of Medicine and the Broad Institute developed a new computer algorithm they call REVEALER.
ROR1, an oncogene recently discovered on chronic lymphocytic leukemia (CLL) B cells, is being studied by researchers as a potential target for CLL treatment. Dr. Brian Koffman met with Dr. Thomas Kipps, who is researching ROR1, at the 2014 American Society of Clinical Oncology (ASCO) meeting to discuss this oncogene and its potential use in treating CLL.
Andrew Schorr from Patient Power in partnership with the CLL Global Research Foundation interview Dr. Thomas Kipps, Director of the Blood Cancer Research Fund and the CLL Research Consortium about the use of rituximab, a monoclonal antibody used to treat patients with chronic lymphocytic leukemia
Dr. Thomas Kipps and scientists from his research laboratory at the UC San Diego Moores Cancer Center discover an association between a protein called ROR1 and EMT, a process that occurs during embryogenesis.
Dr. Thomas Kipps and researchers at the UC San Diego Moores Cancer Center have found a monoclonal antibody named RG7356 that may be effective in in killing chronic lymphocytic leukemia cells without harming healthy cells.